A Phase 1b/2 Study of Demcizumab plus Paclitaxel in Subjects with Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Trial Profile

A Phase 1b/2 Study of Demcizumab plus Paclitaxel in Subjects with Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Demcizumab (Primary) ; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SIERRA
  • Sponsors OncoMed Pharmaceuticals
  • Most Recent Events

    • 16 Sep 2016 Status changed from recruiting to completed.
    • 05 Jan 2016 Results from this trial are expected in 2016, according to an OncoMed media release.
    • 12 Mar 2015 According to the Oncomed media release, company plans to complete ovarian cancer Phase 1b trial (demcizumab plus paclitaxel) and make go/no-go decision on Phase 2 in this indication in 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top